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ABSTRACT: The applicability of MIB-1, a monoclonal antibody directed against the 
Ki-67 antigen, was studied in the PC-82 and LNCaP prostatic tumor models at various levels 
of proliferative activity. Statistically significant correlations were found in LNCaP cultures 
between Ki-67 and MIB-1 scores (r = 0.84, P < O.OOl), and in PC-82 tumors between MIB-1 
scores and paraffin tissue Ki-67 (pKi-67) (r = 0.90, P < 0.001), frozen tissue Ki-67 (fKi-67) 
(r = 0.86, P < 0.001), and BrdU uptake (r = 0.70, P < 0.001), respectively. pKi-67 scores 
were double the fKi-67 scores, which may be due to methodological differences. MIB-1 
scores exceeded both the fKi-67 and pKi-67 scores. The affinity of MIB-1 for the antigen is 
much higher than the affinity of Ki-67, which may explain the differences. MIB-1 is a 
promising means of evaluating the presence of only minute amounts of the Ki-67 antigen in 
paraffin-embedded human tumor material, especially in relatively slowly growing tumors. 
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INTRODUCTION 
Since its description in 1983, much attention has 
been paid to the mouse monoclonal antibody Ki-67 
[l]. 1 -67  is directed against a nuclear antigen ex- 
pressed in human cells during the G1, S, G2, and M 
phases of the cell cycle, but not during the GO phase 
[2]. Quiescent (GO) cells which enter the cell cycle do 
not express the antigen in the early G1 phase [2]. The 
proliferative activity of a number of human tumors, 
including prostatic carcinoma, has been studied by 
the application of Ki-67, as investigated by Oomens et 
al. [3] and reviewed by Brown and Gatter [4]. Routine 
studies were hampered by the fact that Ki-67 was 
thought to be applicable only to fresh-frozen tissues. 
MIB-1 is a recently described mouse monoclonal an- 
tibody raised against recombinant parts of the Ki-67 
antigen, and it is applicable to routinely processed, 
paraffin-embedded tissues following antigen retrieval 
[5,6]. It has recently been shown that Ki-67 also reacts 
with paraffin tissue sections, using this technique [7] .  
DNA-replicating cells can be identified by a mono- 
clonal antibody to BrdU (bromodeoxy-uridine), a thy- 
midine analogue incorporated into DNA in the S 
phase of the cell cycle [8]. BrdU-uptake has been 
studied in human tumors [9-111. The present study 
was performed to investigate the applicability of 
MIB-1 to routinely processed prostate cancer speci- 
mens. 
Two human prostatic tumor models were used in 
the present study: the PC-82 xenograft model which 
is serially transplantable in athymic nude mice [12], 
and the in vitro LNCaP cell line [13]. The growth rate 
of both hormone-dependent tumor models can be 
manipulated by growing the tumors at various an- 
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drogen concentrations [14,15]. The potency of using 
the Ki-67 antibody for monitoring hormonal re- 
sponses in the PC-82 tumor has been described pre- 
viously [ 161. 
In the present study, MIB-1 scores were correlated 
with fKi-67 (frozen tissue Ki-67), pKi-67 (paraffin tis- 
sue Ki-67), and BrdU scores. This was achieved by 
application of the antibodies to frozen or paraffin tis- 
sue sections from the same PC-82 tumor, or to slides 
with acetone-fixed LNCaP cells. Hormonal manipu- 
lation of the PC-82 tumors and LNCaP cells resulted 
in tissues at various levels of proliferative activity. 
Also, a number of radical prostatectomy specimens 
embedded 6-16 years ago were stained with MIB-1 in 
order to investigate the applicability of MIB-1 to ar- 
chival clinical tissues. 
MATERIALS AND METHODS 
Experimental Models 
PC-82 tumor cells were subcutaneously implanted 
in nude mice of Balb/c background. Tumor growth 
was manipulated by implantation of tumor-bearing 
mice with various androgen levels; tumor growth 
could be arrested by androgen withdrawal [14]. BrdU 
(10 mglkg) was injected intraperitoneally 1 hr prior to 
sacrifice of the host animal. After sacrifice of the an- 
imal, tumor sections were either snap-frozen in liquid 
nitrogen-chilled isopentanyl 99% and stored at 
-8O"C, or routinely fixed in 4% formalin in PBS 
(phosphate-buffered saline, pH 7.4) and embedded 
in paraffin. Routinely processed prostatectomy spec- 
imens embedded 6-16 years ago were obtained from 
the Department of Pathology, Dijkzigt Hospital, Rot- 
terdam. To avoid the risk of detachment of cells or 
tissues from the glass slides, APES (3-aminopropyl- 
triethoxysi1ane)-coated slides were used in all exper- 
iments [17]. 
LNCaP-FGC (fast-growing colony) cells were 
seeded on APES-coated slides. The cells were grown 
in 7.5% fetal calf serum at standard conditions as de- 
scribed elsewhere [MI. The culture medium from ex- 
ponentially growing cultures was replaced (after 2 
days) by 5% DCC (dextran-coated charcoal)-treated, 
i.e., androgen-depleted, serum. Slides were fixed in 
acetone for 10 mirn at 0,24,48, 72, and 96 hr following 
androgen withdrawal. The LNCaP experiments were 
performed in triplicate. 
Frozen Tissue Ki-67 (fKi-67) and BrdU Staining 
Ki-67 and BrdU staining procedures have been de- 
scribed previously [3,8]. Briefly, monoclonal anti- 
body Ki-67 (DAKO, Glostrup, Denmark) and a mono- 
clonal antibody specific for BrdU (Eurodiagnostics, 
Apeldoorn, The Netherlands) were applied to 5-pm 
thick frozen and paraffin sections, respectively. Ki-67 
was diluted 1:s in PBS. Antibody-antigen binding 
was visualized using an indirect two-step peroxidase 
method with DAB (3,3'-diaminobenzidine tetrahy- 
drochloride) as chromogen. Prior to application of the 
BrdU antibody, these sections were subsequently 
placed in 2 N HC1 for 30 min to uncoil the DNA, and 
in a borate buffer, pH 8.5, for neutralization [8]. 
Paraffin Tissue Ki-67 (pKi-67) and MIB-I Staining 
The procedure used for MIB-1 staining is the result 
of the optimization of the procedure recommended by 
the manufacturer (Immunotech, Marseille, France). 
An identical procedure was used for pKi-67 staining, 
except for the primary antibody. Paraffin PC-82 and 
prostatectomy sections of 5-pm thickness were cut 
and mounted on APES-coated slides [17]. The slides 
were kept overnight at 60°C. After rehydration, the 
slides were placed in 10 mM citrate buffer adjusted to 
pH 6.0, after which antigen retrieval was performed in 
a microwave oven at 700 W for 15 min [6]. Distilled 
water was regularly added to prevent drying of the 
slides due to evaporation. The slides were allowed to 
cool down to room temperature, and were subse- 
quently rinsed in PBS. Antigen retrieval was omitted 
for the acetone-fixed LNCaP cells. To avoid nonspe- 
cific staining, both tissue sections and LNCaP cultures 
were preincubated for 15 min at 37"c with normal goat 
serum (DAKO) diluted 1 : l O  in PBS. Overnight incu- 
bation with MIB-1 (Immunotech), diluted 1:200 in 
PBS, or with Ki-67 (DAKO), diluted 1 : l O  in PBS, was 
carried out at 4°C. After rinsing in PBS, the sections 
were incubated for 30 min at room temperature with 
a 1:400 dilution of biotinylated goat anti-mouse serum 
(DAKO) in PBS containing 3% normal goat and 3% 
normal human serum. After rinsing in PBS, a final 
incubation with avidin biotin complex (ABC), consist- 
ing of streptavidin and biotinylated horseradish per- 
oxidase diluted in PBS, as described by the manufac- 
turer (DAKO), was performed for 30 min at room 
temperature. The staining was visualized with 0.075% 
DAB (Fluka, Buchs, Germany) in PBS with 0.08% hy- 
drogen peroxide as substrate for 7 min. Sections were 
rinsed in distilled water, and counterstained with 
Mayers hematoxylin. After dehydration, sections 
were mounted with malinol. 
Quantification 
Sections were examined at 400 x magnification. 
The numbers of positive and negative tumor cell nu- 
clei in the 4 x 4 central part of a 10 x 10 grid inserted 
in one of the oculars were counted. Adjacent micro- 
scopical fields were examined until 1,000 or more 
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Fig. I. Well-differentiated adenocarcinoma in a tissue section of 
a 16-year-old radical prostatectomy stained with MIB- I. x 270. 
cells were counted. Cells with an apparent brown 
staining of the nucleus and well-demarcated nucleoli 
were judged positive. Scores are presented as per- 
centages of cells counted. Spearman’s rank correla- 
tions were calculated since the data were not nor- 
mally distributed. For statistical confirmation the 
Student’s t-test was performed using the software 
package SPSS 4.01 (Statistical Package for Social Sci- 
ences, SPSS, Inc., Chicago, IL). 
RESULTS 
lmmunostaining of Prostatectomy Specimens 
Figure 1 shows MIB-1 staining in a 16-year-old 
prostatectomy specimen. Although variations in 
staining intensity were observed, positive and nega- 
tive cells were generally easy to identify. Occasionally 
cytoplasmic staining was observed. Detachment of 
parts of the prostatectomy sections from the glass 
slide was seen, especially in sections containing the 
(fatty) periprostatic tissue. The risk of detachment de- 
creased when the slides, prior to antigen retrieval, 
were kept overnight at 60°C. This procedure did not 
alter the immunoreactivity for MIB-1. 
lmmunostaining of Prostatic Cancer Cell Lines 
Hormonal manipulation of the PC-82 tumor- 
bearing mice resulted in tumors with various growth 
rates, which were clearly reflected by the MIB-1-, 
frozen Ki-67 (fKi-67)-, paraffin 1 -67  (pKi-67)-, and 
BrdU-defined proliferative activities (data not 
shown). Intensity of MIB-1 staining was in general 
more pronounced than intensity of fKi-67 and pKi-67 
staining. Weak nuclear MIB-1 staining could still 
be observed when the antibody was diluted 1:5,000 
(0.04 pg/ml). Ki-67 staining decreased at a concen- 
tration of 3.96 pg/ml (1:50 dilution). Only little 
intratumoral variation in the dispersion of positive 
nuclei was observed. MIB-1 scores ranged from 0.1- 
25.7% (mean 11.6%), fKi-67 scores ranged from 
0.2-6.8% (mean 2.9%), pKi-67 scores ranged from 
0.6-18.5% (mean 6.7%), and BrdU scores ranged 
from 0.0-7.5% (mean 2.4%). Figure 2 shows fKi-67 
staining (Fig. 2A), pKi-67 staining (Fig. 2B), and 
MIB-1 staining (Fig. 2C) in sections taken from one 
PC-82 tumor. In PC-82 tissues a highly significant cor- 
relation was found between MIB-1 and fKi-67 scores 
(r = 0.86, P < 0.001, n = 21), and between MIB-1 and 
pKi-67 scores (r = 0.90, P < 0.001, n = 25), as de- 
picted in Figure 3. Relatively weak correlations were 
found between MIB-1 scores and BrdU-uptake, as 
shown in Figure 4 (r = 0.70, P < 0.001, n = 24), and 
between fKi-67 scores and BrdU-uptake (r = 0.44, P 
= 0.052, n = 20). The correlation between fKi-67 and 
pKi-67 scores was 0.77 ( P  < 0.001, n = 21). MIB-1 
scores exceeded both the fKi-67 scores (linear regres- 
sion coefficient p = 3.67, 95% confidence interval 
(CI): 2.87-4.47) and the pKi-67 scores (p = 1.57, CI: 
1.28-1.86). pKi-67 scores were double the fKi-67 
scores (p = 2.03, CI: 1.31-2.75). 
The acetone-fixed LNCaP cultures did not require 
antigen retrieval prior to application of MIB-1. The 
growth-inhibiting effect of androgen depletion on the 
LNCaP cells was clearly reflected by a loglinear de- 
cline of Ki-67 and MIB-1 scores, representing the exit 
of cells from the cell cycle (Fig. 5). The MIB-1 and 
Ki-67 scores observed in LNCaP cultures were gen- 
erally larger than those observed in PC-82 tissue sec- 
tions, and ranged from 16-70% (mean, 39.6) for 
MIB-1, and from 7-4170 (mean, 19.8) for Ki-67. MIB-1 
scores were almost double the Ki-67 scores (p = 1.81, 
CI: 1.44-2.18), and the correlation coefficient was 
0.84 (P  < 0.001, n = 15). 
DISCUSSION 
The present study was conducted to compare the 
novel proliferation marker MIB-1 with frozen tissue- 
based Ki-67 (fKi-67), paraffin tissue-based Ki-67 
(pKi-67), and BrdU uptake. This was achieved by im- 
munostaining samples derived from hormonally ma- 
nipulated PC-82 tumors and LNCaP cell cultures with 
the different antibodies [1,5,7,8]. In LNCaP cultures 
only Ki-67 and MIB-1 were studied. MIB-1 staining 
was also studied in archival radical prostatectomy 
specimens. 
Antigen retrieval is essential for immunostaining 
with the MIB-1 or the Ki-67 (pKi-67) antibodies when 
applied to paraffin-embedded tissue sections. As 
found by others [19], application of MIB-1 without 
antigen retrieval only stained mitotic cells (not 
shown). The mechanism of antigen retrieval remains 
unclear as yet, but it has been suggested that the 
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Fig. 2. lmmunostaining of a PC-82 tumor sample (grown in a hormonally untreated mouse). A: 
Fresh-frozen section, Ki-67 (fKi-67). B: Paraffin-embedded section, Ki-67 (pKi-67). C: Paraffin- 
embedded section, MIB- I ( X 270). Some positive nuclei are indicated with arrows. 
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Fig. 3. Correlations between MIB-l scores and the respective 
fKi-67 (frozen tissue-based Ki-67) scores and pKi-67 (paraffin t is-  
sue-based Ki-67) scores, assessed on PC-82 tumor samples (n = 
21). Note the difference in scaling of the axes. Regression lines: 
fKi-67 (solid line), pKi-67 (dotted line). 
formalin-induced protein crosslinkings are broken 
with this procedure, thus unmasking the epitopes of 
the various antigens [6]. In the present study MIB-1 
staining could still be observed in a 16-year-old pros- 
tatectomy specimen. Cattoretti et al. [19] detected 
MIB-1 reactivity in a 60-year-old Zenkers’ fixed lymph 
node. Cytoplasmic staining was occasionally ob- 
served in some of the prostatectomy specimens. A 
similar cytoplasmic staining has also been described 
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Fig. 4. Correlation between MIB- I scores and BrdU-uptake in 
24 PC-82 tumors. Note the difference in scaling of the axes. 
in prostatic tissues stained by Ki-67, but appears not 
to be associated with proliferation [20]. fKi-67, pKi- 
67, and especially MIB-1 staining were not always 
equal in intensity, as Figure 2 shows. This may com- 
plicate the distinction of positive and negative cells. 
In the present study, cells were scored positive only 
when both nuclear and nucleolar staining were visi- 
ble. If cells showing only one of these patterns were 
included, scores would have been higher in a number 
of the sections. 
Strong and statistically significant correlations 
were found between MIB-1 and fKi-67 scores (r = 
158 Noordzij et al. 
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Fig. 5. The relation of MIB- I (dotted line) and Ki-67 scores (solid 
line) to  time in a time-course experiment with hormone respon- 
sive LNCaP cells following androgen withdrawal at day 0 (mean ? 
SD). 
0.86, P < 0.001), between MIB-1 and pKi-67 scores 
(r = 0.90, P < 0.001) in PC-82 tumors (Fig. 3), and 
between MIB-1 and Ki-67 scores (r = 0.84, P < 0.001) 
in LNCaP cultures (Fig. 5). Surprisingly, MIB-1 scores 
exceeded both the fKi-67 scores (p = 3.67) and the 
pKi-67 scores (p = 1.57) in PC-82 sections. The meth- 
odological differences between the fKi-67 and MIB-1 
staining procedures probably partially account for 
this discrepancy. However, the staining procedures 
were identical for Ki-67 and MIB-1 applied to paraffin 
PC-82 sections (p = 1.57) and LNCaP cultures (p = 
1.81). Still, a marked difference was observed in both 
cases as demonstrated by the regression coefficients. 
The described intensity difference between MIB-1 
and Ki-67 labelling might partially account for this 
discrepancy. McCormick et al. [21] have also shown a 
close relationship between MIB-1 and Ki-67 scores. 
However, based upon other types of tissue, they did 
not describe the discrepancy found in the present 
study. It has very recently been shown that the nu- 
clear Ki-67 protein, i.e., the protein recognized by 
Ki-67, can exist free or associated with double-strand 
DNA [22]. This study demonstrated that, in contrast 
to Ki-67, MIB-1 recognizes the free protein. More- 
over, the affinity of MIB-1 for the DNA Ki-67 protein 
complex largely exceeds the affinity of Ki-67 for that 
complex [22]. This indicates that binding of the Ki-67 
protein to the DNA modulates its conformation, 
which makes it an antigen for both Ki-67 and MIB-1. 
Since MIB-1 was raised against recombinant ex- 
pressed Ki-67 protein, it was to be expected that 
MIB-1 would also recognize free Ki-67 protein. These 
results provide at least one plausible explanation for 
the differences between the Ki-67 and MIB-1 scores 
found in the present study. Furthermore, weak nu- 
clear staining could still be observed when MIB-1 was 
applied at a dilution of 1:5,000 (0.04 kg/ml), whereas 
nuclear Ki-67 staining decreased at a dilution of 1:50 
(3.64 pg/ml) . 
Expectedly, BrdU pulse labeling scores are smaller 
than Ki-67 and MIB-1 scores [9,23]. Van Dierendonck 
et al. [24] have shown that Ki-67 scores cannot auto- 
matically be used to determine the growth fraction of 
a tumor. Therefore, the relatively weak correlations 
found between Ki-67 and BrdU, and between MIB-1 
and BrdU, are not surprising. Sasaki et al. [9] de- 
scribed a correlation coefficient of 0.89 between Ki-67 
and BrdU scores in 20 malignant human tumors. The 
proliferation scores in their study (1.9-37.5% for 
Ki-67 and 1.6-23.4% for BrdU) were generally larger 
than the scores found in the present study. In a study 
of Van Weerden et al. [23] using the PC-82 tumor 
model, the correlation between Ki-67 and BrdU 
scores was comparable to that found in the present 
study. The clinical use of BrdU uptake is hampered as 
administration of BrdU to a patient may cause acute 
toxic reactions and/or chromosomal abnormalities 
[25,26]. 
In conclusion, MIB-1 is a promising antibody and 
allows for the detection of very small amounts of the 
Ki-67 antigen in routinely processed, paraffin-embed- 
ded archival tissues. MIB-1 might be of special value 
in tumors with relatively small growth fractions, such 
as prostatic carcinomas. At our institution a retro- 
spective study to determine the prognostic value of 
MIB-1 in prostate cancer patients is currently in 
progress. 
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